



EDITORIALS

373 Disgust – the forgotten emotion of psychiatry

M. L. Phillips, C. Senior, T. Fahy and A. S. David

376 Reserpine exhumed

D. Healy and M. Savage

379 People with dementia can remember. Implications for care

D. D. R. Williams and J. Garner

REVIEW ARTICLES

Self-injurious behaviour in people with a learning disability

381 Self-injury and violence in people with severe learning disabilities

S. Read

385 Self-injurious behaviour as part of genetic syndromes

S. Deb

389 Psychopharmacology of severe self-injury associated with learning disabilities

D. J. Clarke

395 Psychological interventions in self-injurious behaviour. Working with people with a learning disability

S. Halliday and K. Mackrell

PAPERS

401 Auditing electroconvulsive therapy. The third cycle

R. Duffett and P. Lelliott

406 Home self-assessment of obsessive-compulsive disorder. Use of a manual and a computer-conducted telephone interview: two UK-US studies

I. M. Marks, L. Baer, J. H. Greist, J. M. Park, M. Bachofen, A. Nakagawa, K. W. Wenzel, J. R. Parkin, P. A. Manzo, S. L. Dotti and J. M. Mantle

413 Randomised controlled trial of compliance therapy. 18-month follow-up

R. Kemp, G. Kirov, B. Everitt, P. Hayward and A. David

420 Cost-effectiveness evaluation of compliance therapy for people with psychosis

A. Healey, M. Knapp, J. Astin, J. Beecham, R. Kemp, G. Kirov and A. David

425 Amnesic people with Alzheimer's disease who remembered the Kobe earthquake

M. Ikeda, E. Mori, N. Hirono, T. Imamura, T. Shimomura, Y. Ikejiri and H. Yamashita

429 Epidemiology of paranoid symptoms in an elderly population

Y. Forsell and A. S. Henderson

433 Detecting postnatal depression in Chinese women. Validation of the Chinese version of the Edinburgh Postnatal Depression Scale

D. T. S. Lee, S. K. Yip, H. F. K. Chiu, T. Y. S. Leung, K. P. M. Chan, I. O. L. Chau, H. C. M. Leung and T. K. H. Chung

438 Prolactin response to d-fenfluramine is blunted in people with anorexia nervosa

P. Montealeone, F. Brambilla, F. Bortolotti, A. La Rocca and M. Maj

PRELIMINARY REPORT

443 Post-traumatic stress disorder in children and adolescents following road traffic accidents

K. A. H. Mirza, B. R. Bhadrinath, I. M. Goodyer and C. Gilmour

COLUMNS

448 Correspondence

454 One hundred years ago

455 Book reviews

456 Contents of *The American Journal of Psychiatry*



EDITOR Greg Wilkinson LIVERPOOL

EDITORIAL BOARD

DEPUTY EDITOR

Alan Kerr
NEWCASTLE UPON TYNE

ASSOCIATE EDITORS

Sidney Crown
LONDON
Julian Leff
LONDON
Sir Martin Roth, FRS
CAMBRIDGE
Sir Michael Rutter, FRS
LONDON
Peter Tyrer
LONDON

EDITORIAL ADVISERS

Tony Johnson
CAMBRIDGE
Kathleen Jones
YORK
Martin Knapp
LONDON
Herschel Prins
LEICESTER
Sir John Wood
SHEFFIELD

ASSISTANT EDITORS

Louis Appleby
MANCHESTER
Alistair Burns
MANCHESTER
Patricia Casey
DUBLIN
John Cookson
LONDON

Tom Fahy
LONDON

Anne Farmer
CARDIFF

Michael Farrell
LONDON

Nicol Ferrier
NEWCASTLE UPON TYNE

Richard Harrington
MANCHESTER

Sheila Hollins
LONDON

Jeremy Holmes
BARNSTAPLE

Michael King
LONDON

Michael Kopelman
LONDON

Alan Lee
NOTTINGHAM

Glyn Lewis
CARDIFF

Shôn Lewis
MANCHESTER

Robin McCreadie
DUMFRIES

Ian McKeith
NEWCASTLE UPON TYNE

J. Spencer Madden
UPTON-BY-CHESTER

David Owens
LEEDS

Ian Pullen
MELROSE

Henry Rollin
LONDON

Jan Scott
NEWCASTLE UPON TYNE

Andrew Sims
LEEDS

George Stein
LONDON

CORRESPONDING EDITORS

Andrew Cheng
TAIWAN

Kenneth Kendler
USA

Arthur Kleinman
USA

Paul Mullen
AUSTRALIA

Michele Tansella
ITALY

J. L. Vázquez-Barquero
SPAIN

STATISTICAL ADVISER

Pak Sham
LONDON

STAFF

PUBLICATIONS MANAGER
Dave Jago

DEPUTY MANAGER
Helen Bolton

SCIENTIFIC EDITOR
Andrew Morris

ASSISTANT SCIENTIFIC EDITORS
Lucretia King
Zoë Stagg

EDITORIAL ASSISTANTS
Zofia Ashmore

Julia Burnside
Rachel Gold

MARKETING ASSISTANT
Dominic Bentham

Subscriptions

Non-members of the College should contact the Publications Subscription Department, Royal Society of Medicine Press Limited, PO Box 9002, London W1A 0ZA (tel. 0171 290 2928; fax 0171 290 2929). Annual subscription rates for 1998 (12 issues post free) are as follows:

	INSTITUTIONS	INDIVIDUALS
Europe (& UK)	£172	£150
US	\$350	\$258
Elsewhere	£205	£162

Full airmail is £36/
US\$64 extra.

Single copies of the
journal are £14, \$25
(post free).

Queries from non-members about missing or faulty copies should be addressed within six months to the same address; similar queries from College members should be addressed to the Registration Subscription Department, The Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG.

Payment should be made out to the British Journal of Psychiatry.

Back issues

Back issues published before 1996 may be purchased from William Dawson & Sons Ltd, Cannon House, Folkestone, Kent (tel. 01303 850 101).

Advertising

Correspondence and copy should be addressed to Peter T. Mell, Advertising Manager, PTM Publishers Ltd, 282 High Street, Sutton, Surrey SMI 1PQ (tel. 0181 642 0162; fax 0181 643 2275).

US Mailing Information

The *British Journal of Psychiatry* is published monthly by the Royal College of Psychiatrists. Subscription price is \$350. Second class postage paid at Rathway, NJ. Postmaster send address corrections to the British Journal of Psychiatry, c/o Mercury Airfreight International Ltd Inc., 2323 Randolph Avenue, Avenel, New Jersey 07001.

The paper used in this publication meets the minimum requirements of the American National Standard for Information Sciences - Permanence of Paper for Printed Library Materials, ANSI Z39.48-1984.

Typeset by Dobbie Typesetting Ltd, Tavistock.

Printed by Henry Ling Ltd, The Dorset Press, 23 High East Street, Dorchester, Dorset DT1 1HD.

Past Editors

Eliot Slater	1961-72	John L. Crammer	1978-83
Edward H. Hare	1973-77	Hugh L. Freeman	1984-93

Founded by J. C. Bucknill in 1853 as the *Asylum Journal* and known as the *Journal of Mental Science* from 1858 to 1963.

©1998 The Royal College of Psychiatrists. Unless so stated, material in the *British Journal of Psychiatry* does not necessarily reflect the views of the Editor or the Royal College of Psychiatrists. The publishers are not responsible for any error of omission or fact.


The *British Journal of Psychiatry* is published monthly by the Royal College of Psychiatrists (a registered charity, registration number 228636). The *BJP* publishes original work in all fields of psychiatry. Manuscripts for publication should be sent to the Editor, *British Journal of Psychiatry*, 17 Belgrave Square, London SW1X 8PG. Queries, letters to the Editor and book reviews may also be sent electronically to zashmore@rcpsych.ac.uk.

Instructions to authors

Full instructions to authors are given at the beginning of the January and July issues, and on the Web Site below. Copies are also available from the Journal Office.

Information about the College's publications is available on the World Wide Web at <http://www.rcpsych.ac.uk>.


Debbie doesn't know that Cipramil is now indicated for panic disorder



... she just knows her doctor
made a logical choice

As a patient with Panic Disorder, Debbie is beginning to appreciate the value of the Cipramil treatment that her doctor has newly prescribed.

Of course, Debbie would no more talk of the recently extended indication for Cipramil than its high selectivity^{1,2}, good tolerability³, and low risk of drug interactions^{4,5}. She just recognises the difference that Cipramil makes to the stability and quality of her life.



Cipramil[▼] citalopram

now indicated for panic disorder

Presentation: 'Cipramil' tablets 10 mg; PL 0458/0057, each containing 10 mg of citalopram as the hydrobromide. 28 (OP) 10 mg tablets £12.77. 'Cipramil' tablets 20 mg; PL 0458/0058, each containing 20 mg of citalopram as the hydrobromide. 28 (OP) 20 mg tablets £21.28. **Indications:** Treatment of depressive illness in the initial phase and as maintenance against relapse/recurrence. Treatment of panic disorder, with or without agoraphobia. **Dosage: Treating depression: Adults:** 20 mg a day. Depending upon individual patient response, this may be increased in 20 mg increments to a maximum of 60 mg. Tablets should not be chewed, and should be taken as a single oral daily dose, in the morning or evening without regard for food. Treatment for at least 6 months is usually necessary to provide adequate maintenance against the potential for relapse. **Treating panic disorder:** 10 mg daily for the first week, increasing to 20 mg daily. Depending upon individual patient response, dosage may be further increased to a maximum of 60 mg daily. Depending upon individual patient response, it may be necessary to continue treatment for several months. **Elderly:** 20 mg a day increasing to a maximum of 40 mg dependent upon individual patient response. **Children:** Not recommended. **Reduced hepatic/renal function:** Restrict dosage to lower end of range in hepatic impairment. Dosage adjustment not necessary in cases of mild/moderate renal impairment. No information available in severe renal impairment (creatinine clearance <20ml/min). **Contra-indications:** Combined use of 5-HT agonists. Hypersensitivity to citalopram. **Pregnancy and Lactation:** Safety during human pregnancy and lactation has not been established. Use only if potential benefit outweighs possible risk. **Precautions:** Driving and operating machinery. History of mania. Caution in patients at risk of

cardiac arrhythmias. Do not use with or within 14 days of MAO inhibitors: leave a seven day gap before starting MAO inhibitor treatment. Use a low starting dose for panic disorder, to reduce the likelihood of an initial adrenergic effect (experienced by some patients) when starting pharmacotherapy. **Drug Interactions:** MAO inhibitors (see Precautions). Use lithium and tryptophan with caution. Routine monitoring of lithium levels need not be adjusted. **Adverse Events:** Most commonly nausea, sweating, tremor, somnolence and dry mouth. With citalopram, adverse effects are in general mild and transient. When they occur, they are most prominent during the first two weeks of treatment and usually attenuate as the depressive state improves. **Overdosage:** Symptoms have included somnolence, coma, sinus tachycardia, occasional nodal rhythm, episode of grand mal convulsion, nausea, vomiting, sweating and hyperventilation. No specific antidote. Treatment is symptomatic and supportive. Early gastric lavage suggested. **Legal Category:** POM 24.1.95. Further information available upon request. Product licence holder: Lundbeck Ltd., Sunningdale House, Caldecotte Lake Business Park, Caldecotte, Milton Keynes, MK7 8LF. © 'Cipramil' is a Registered Trade Mark. © 1997 Lundbeck Ltd. Date of preparation: April 1997. 0897/CIP/501/044

1. Hyttel J. XXII Nordiske Psykiater Kongres, Reykjavik, 11 August 1988:11-21. 2. Eison AS et al Psychopharmacology Bull 1990; 26 (3): 311-315. 3. Wade AG et al. Br J Psychiatry 1997; 170: 549-553. 4. Sindrup SH et al. Ther Drug Monit 1993; 15: 11-17. 5. Van Harten J. Clin Pharmacokinetics 1993; 24: 203-20. 6. Jeppesen U et al. Eur J Clin Pharmacol 1996; 51: 73-78.

SEXUAL OFFENDERS

Assessment, Risk Management and Treatment

A 3-day conference with
featured expert presenters

Gene Abel, MD: Pedophiles & Child Molesters
Anna Salter, PhD: Risk Assessment
Fred Berlin, MD, PhD: Assessing & Treating

Regent's College, London
1-3 July, 1998

Presented by Specialized Training Services
in conjunction with NOTA

For a complete conference brochure, contact:

Carolyn Martinson, NOTA Administrator
The Office
50 Hayburn Avenue
Hull HU5 4NA

Tel: 01482 343625

Fax: 01482 472161

EAST RIDING CANCER SERVICES ALLIANCE
in conjunction with
INSTITUTE OF REHABILITATION,
UNIVERSITY OF HULL

MEETING THE PSYCHOSOCIAL NEEDS OF CANCER PATIENTS AND THEIR FAMILIES

A National Symposium

29 May, 1998

East Riding Medical Education Centre
Hull Royal Infirmary

Speakers include:

Dr Leslie Walker
Dr C. Pitceathly
Prof. Lesley Fallowfield
Dr Alison Richardson
Prof. Amanda Ramirez
Dr Alan House
Dr Peter Harvey

Cost: £75.00
(£25.00 concessionary rate for staff of East Riding
Cancer Services Alliance partner organisations)

For further details please contact:

Rosemary Thorpe

Tel: 01482 806009

Fax: 01482 806968

FORENSIC CONFERENCE

A 4-day event in Holland with
featured expert presenters

Phillip Resnick, MD

Risk Assessment of the Mentally Ill Individual
Clinical Assessment of Malingering-Deception
The Mental Health Professional in Court

25-26 June, 1998

Reid Meloy, PhD

Personality Testing in Forensic Evaluations
Forensic Psychological Investigation

29-30 June, 1998

The Dr Henri van der Hoeven Kliniek
Utrecht, The Netherlands

Presented by Specialized Training Services
with the Dr Henri van der Hoeven Kliniek

For a complete conference brochure, contact:
Quina Drost, Postbus 174, 3500 AD Utrecht,
The Netherlands

Tel: +31 30 275 8275

Fax: +31 30 275 8200

LISTER

O

C

U

N

*Psychiatrists
Urgently Required
All Grades
Immediate Bookings
Excellent Rates- (negotiable)
Prompt Weekly Payments*

*"The friendly,
personal
approach to
business"*

Please call
Andy on:
Freephone
0800 298 1780
or fax CV
details to:
01253 730398

LTD



ATTENTION ALL CONSULTANT PSYCHIATRISTS

- * We have long/short term positions available to start IMMEDIATELY.
- * General/Adult/Old Age/Child & Family/Drug & Substance Abuse and Learning Disabilities.

ALL AREAS

EXCELLENT RATES

IMMEDIATE STARTS

CASH PAYMENTS

We have specialist staff waiting to hear from you in these areas:

SOUTHAMPTON

MANCHESTER

& LONDON (M25 corridor)

DON'T DELAY

Southern Division

76 Portswood Road, Portswood,
Southampton SO17 2FW

Tel: 01703 393988; Fax: 01703 393908

Northern Division

24-26 Brook Street, Chadderton,
Oldham OL9 6NN

Tel: 0161 2902020; Fax: 0161 2903030
Email: direct@interalpha.co.uk

GASKELL ACADEMIC SERIES

The Analysis of Hysteria

Second Edition

Understanding Conversion and Dissociation

By Harold Merskey

This book is a substantial update and enlargement of the first edition, which received exceptionally good reviews when first published in 1979. It provides a survey of the topics which have been included under the name of hysteria and which are still of importance under the terms conversion and dissociation. Current concepts of repression, including the common modern problems of "multiple personality disorder" and "recovered memory" are discussed in detail. The whole range of hysterical phenomena is covered, from classical paralyses and blindness to questions about hysterical personality and epidemic hysteria. £30.00, 486pp., Hardback, 1995, ISBN 0 902241 88 5

Gaskell is the imprint of the Royal College of Psychiatrists. Gaskell books are available from good bookshops and from the Publications Department, Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG (Tel. +44(0)171 235 2351, extension 146). The latest information on College publications is available on the INTERNET at: <http://www.demon.co.uk/rcpsych/>



P S Y C H I A T R I S T S

If you're trying to
provide the best in
mental healthcare,
this is a good place
to start.

For a clean, unspoiled environment, wide-open spaces and a free and accommodating lifestyle, New Zealand has few if any, equals. Perhaps it's this national desire for peace of mind that lies behind our approach to mental healthcare.

To a Psychiatrist with ambitions, the biggest source of professional frustration is likely to be the gap that exists between the *right* mental healthcare and the mental healthcare that the budget allows.

Arguably, that gap is smaller in New Zealand than anywhere else in the world. And no one is about to become more committed to do this than Auckland Healthcare.

At Auckland Healthcare, the largest healthcare provider in the country, we are totally committed to the concept of community mental healthcare and we are investing significantly in its future.

Without compromise. In this respect, as in many others, Auckland Healthcare's Mental Health Services (MHS) is leading the way.

Today, our comprehensive portfolio of mental health services includes Homeless Mental Health, Maternal Mental Health, Maori and Pacific Island Mental Health, Behaviour Support, Child and Family Support, Liaison Psychiatry and Respite Services, as well as a range of Acute and Non-Acute services delivered in both hospital and the home.

MHS also enjoys a particularly close and productive relationship with Auckland Hospital (a major teaching hospital) and The University of Auckland's School of Medicine. As a result, we can offer a variety of ongoing educational and research opportunities, including a possibility of honorary lectureships at the University. Individual interests can be discussed and requested where appropriate. Specific vacancies exist in the community, however all interested individuals should apply, as negotiation is possible.

If you are a Registered Psychiatrist and you have a genuine desire to explore the limits of your potential in an environment where mental healthcare comes first, please call Dr Murray Patton, Director of Psychiatry, phone 64-9-623 4676.

Written applications with CV (copy only) to Human Resource Department, Mental Health Services, Private Bag 92605, Symonds Street, Auckland, New Zealand. Please quote Job No. 696 when applying. Email: natashab@ahsl.co.nz

Please ensure that your CV is a copy only, as we have a policy of not returning CVs.



Auckland Healthcare

Te Toka Oranga O Tamaki Makau Rau





There's a depressed patient sitting in front of you. Ask them if it's good to talk.

Communicating confidently, whether it's at work or with friends and family, is just one sign of how well a depressed patient is re-adapting socially. And social interaction is an extremely valuable measure of successful treatment.

Edronax is a new selective NorAdrenaline Re-uptake Inhibitor (NARI). It not only lifts depressed mood,¹ but also significantly improves social interaction.²

These improvements in social functioning have been trial-proven by using the innovative SASS questionnaire (Social Adaptation Self-evaluation Scale).³

Edronax improves mood one week earlier than fluoxetine.¹ Additionally, when compared to fluoxetine, Edronax shows a significantly better outcome in terms of social functioning.²

Edronax helps restore patients' appreciation of friends, family, work and hobbies, and improves their self-perception.

Prescribe 4mg b.d. then make your usual assessments, to see the Edronax difference. The SASS questionnaire, which patients can complete in their own time, may also help.

For free copies of the SASS questionnaire, please telephone 01908 603083.



**A NEW SELECTIVE NARI. LIFTS DEPRESSION.
HELPS RESTORE SOCIAL INTERACTION.**

EDRONAX® ABBREVIATED PRESCRIBING INFORMATION

Presentation: Tablets containing 4mg reboxetine. **Indications:** Use in the acute treatment of depressive illness, and maintenance of clinical benefit in patients responsive to treatment. **Poology and method of administration:** Adults 4 mg b.i.d. (8 mg/day) administered orally. After 3-4 weeks, can increase to 10 mg/day. **Elderly and children** Elderly patients have been studied in comparative clinical trials at doses of 2 mg b.i.d., although not in placebo controlled conditions. There is no experience in children and therefore reboxetine cannot be recommended in either of these groups. **Renal/hepatic**


Special warnings and precautions for use: Close supervision is required for subjects with a history of convulsive disorders and must be discontinued if the patient develops seizures. Avoid concomitant use with MAO inhibitors. Close supervision of bipolar patients is recommended. Close supervision should be applied in patients with current evidence of urinary retention, glaucoma, prostatic hypertrophy and cardiac disease. At doses higher than the maximum recommended, orthostatic hypotension has been observed with greater frequency. Particular attention should be paid when administering reboxetine with other drugs known to lower blood pressure. **Interactions with other medicaments**

that have a narrow therapeutic margin and are metabolised by CYP3A4 or CYP2D6 e.g. anti-arrhythmics (flecainide), anti-psychotic drugs and tricyclic anti-depressants. No pharmacokinetic interaction with lorazepam. Reboxetine does not appear to potentiate the effect of alcohol. **Pregnancy and lactation:** Reboxetine is contraindicated in pregnancy and lactation. **Effects on ability to drive and use machines:** Reboxetine is not sedative per se. However, as with all psychoactive drugs, caution patients about operating machinery and driving. **Undesirable effects:** Adverse events occurring more frequently than placebo are: dry mouth, constipation, insomnia, paraesthesia, increased sweating,

required. **Package and NHS Price:** Pack of 60 tablets in blisters £19.80. **Legal Category:** POM **Marketing Authorisation Holder:** Pharmacia & Upjohn Limited, Davy Avenue, Milton Keynes, MK5 8PH, UK. **Marketing Authorisation Number:** PL 0032/0216. **Date of Preparation:** October 1997. **References:** 1. Montgomery SA. *Journal of Psychopharmacology* 1997 (in press). 2. Dubini A. et al. *European Neuropsychopharmacol.* 1997; 7 (Suppl 1): S57-S70. 3. Bosc M. et al. *European Neuropsychopharmacol.* 1997; 7 (Suppl 1): S57-S70. Further information is available from Pharmacia & Upjohn Limited, Davy Avenue, Knowlhill, Milton

INITIATED UNDER THE AUSPICES OF THE EUROPEAN COMMUNITY.

SUPPORTED BY PFIZER INTERNATIONAL, MAIN SPONSOR.



THE EUROPEAN CERTIFICATE IN ANXIETY AND MOOD DISORDERS

THIS INTERNATIONAL POST GRADUATE PROGRAMME PROVIDES AN OVERVIEW OF THE MOST RECENT SCIENTIFIC DEVELOPMENTS IN THE FIELD OF AFFECTIVE DISORDERS. LECTURES AND SEMINARS ARE GIVEN BY A PANEL OF LEADING SCIENTISTS DURING INTENSIVE RESIDENTIAL SESSIONS, WITH AMPLE OPPORTUNITY FOR INFORMAL EXCHANGES.

THE BOARD OF DIRECTORS ANNOUNCES THE XTH CERTIFICATE

TO TAKE PLACE IN

FONTEVRAUD, FRANCE, 5 - 10 OCTOBER 1998.

THIS CERTIFICATE WILL BE ON ANXIETY DISORDERS, THE 1999 COURSE ON MOOD DISORDERS. SUCCESSFUL TRAINEES ARE AWARDED THE EUROPEAN CERTIFICATE IN ANXIETY AND MOOD DISORDERS, ENDORSED BY THE **MAASTRICHT UNIVERSITY**.

FEES ARE 750 HFL, COVERING FULL ACCOMMODATION.

INFORMATION AND APPLICATION FORMS: (DEADLINE 31 AUGUST 1998)



E.J.L. GRIEZ, CHAIRMAN OF THE BOARD OF DIRECTORS
MAASTRICHT UNIVERSITY, P.O. BOX 616
6200 MD MAASTRICHT
PHONE : +31 (0)43 - 3685332
FAX : +31 (0)43 - 3685331
E-MAIL : ERIC.GRIEZ@PN.UNIMAAS.NL

OR ONE OF THE OTHER DIRECTORS:

J P BOULENGER, MONTPELLIER FAX: + 33 (0)4 673 38995
C. FARAVELLI, FLORENCE FAX: + 39 55 574744
J. ZOHAR, TEL AVIV FAX: + 972 3 5352788
D. NUTT, BRISTOL FAX: + 44 117 9277057

NOTTINGHAM UNIVERSITY
DIVISION OF PSYCHIATRY

**SCHEDULES FOR CLINICAL
ASSESSMENT IN
NEUROPSYCHIATRY (SCAN)**

TRAINING COURSE

Monday 8 June–Friday 12 June, 1998

Nottingham is a SCAN training centre. This course will give full training in the use of SCAN incorporating the latest version of PSE-10. The week will include seminars, small group tutorials and clinical interviews. Continuing professional development (CPD) approval has been applied for. There are limited places available. To apply, please contact:

Miss M. A. Eastwood
Division of Psychiatry
University of Nottingham
Duncan MacMillan House
Porchester Road
Nottingham NG3 6AA

Tel: 0115 952 9406

Fax: 0115 952 9483

The

XI World Congress of Psychiatry

will take place in Hamburg, Germany, from 6–11 August 1999. Its theme will be 'Psychiatry on New Thresholds'.

Deadlines to remember:

- Submission of proposal for Symposia, Workshops and Courses 15 April 1998
- Submission of proposal for Papers, Posters and Videos 31 December 1998
- Early Registration for the Congress 1 February 1999

For further information please contact:

CPO Office Hamburg
Hanser & Co GmbH
Postbox 1221
D-22882 Barsbüttel
Germany

Telephone: +49 40 670 8820

Telefax: +49 40 670 3283

e-mail: cop@wpa-hamburg.de

**SSR Medical Services
SPECIALISTS IN PSYCHIATRY**

Locum and substantive posts available
in London and all major cities
throughout the UK

We would be pleased to discuss
the assignments currently available.

Please contact Liz Goodwin
or her team on:-

Telephone 0181 626 3117

Fax 0181 626 3101

email: lgoodwin@ssrgroupservices.cix.co.uk

**We work for you,
when you work for us.**

We are confident you will enjoy dealing
with our professional, knowledgeable and
caring consultants.



SSR Group Services
5 Blackhorse Lane
London E17 6DN



SSR Medical Services is a division of SSR Group Services Ltd



**K E E L E
UNIVERSITY**

SCHOOL OF POSTGRADUATE MEDICINE
DEPARTMENT OF PSYCHIATRY

DIPLOMA and MSc courses in General Psychiatry

Commencing September 1998

Part-time courses for registered medical practitioners offering an opportunity to update knowledge and skills in general psychiatry.

Diploma Suitable for affiliates of the College, GPs and all non-training grades, this one year course provides an overview of current research and practice based on MRCPsych Part 1 syllabus. Students attend one afternoon of lectures in term-time and work on clinical case studies under individual supervision.

MSc Students who achieve a pass with credit or above or who have gained part 1 MRCPsych may apply for the MSc. A two year course based on the MRCPsych Part 2 syllabus. Formal teaching takes place one afternoon per week. In addition students receive tutorials and seminars on critical reading, presentation skills, research methods and have the option of taking a specialist subject in which they undertake literature reviews and complete a dissertation:-

- Liaison Psychiatry
- Perinatal Psychiatry
- Social and Community Psychiatry
- Substance Abuse
- Transcultural Psychiatry

All students are allocated a personal academic supervisor.

For further details contact: Miss Tracy Brittain, Department of Psychiatry, School of Postgraduate Medicine, Thornburrow Drive, Hartshill, Stoke-on-Trent ST4 7QB. Tel: (01782) 554019, Fax: (01782) 747319.

"Now I can stay awake until bedtime"

FOR MOST PATIENTS, SCHIZOPHRENIA IS A LIFELONG DISEASE REQUIRING LIFELONG MEDICATION. SEDATION IS THE MOST COMMON SINGLE SIDE-EFFECT OF ANTIPSYCHOTIC MEDICATIONS¹ AND ITS POTENTIAL IMPACT ON COMPLIANCE AND QUALITY OF DAILY LIFE IS THEREFORE AN IMPORTANT ISSUE TO CONSIDER.

TRIALS WITH SERDOLECT HAVE DEMONSTRATED PLACEBO-LEVEL SEDATION²

By separating efficacy from sedation, Serdolect gives physicians greater flexibility in patient management - in acute psychotic disturbance, Serdolect may be safely combined with a benzodiazepine³.

SERDOLECT ADDITIONALLY OFFERS

- Efficacy against positive and negative symptoms of schizophrenia^{3,4}
- EPS at placebo level³
- Prolactin levels maintained within normal limits³
- Once-daily dosage

REFERENCES

1. American Psychiatric Association. Practice Guidelines for the treatment of patients with schizophrenia. Supplement to Am. J. Psychiatry 1997; 154(4)
2. Data on file, H. Lundbeck A/S
3. Zimbroff DL et al. Am. J. Psychiatry 1997;154:782-791
4. Hale A. et al. Poster presented at CINP meeting, June 1996, Melbourne



Serdolect[®]

sertindole

Success is a long-term achievement

SERDOLECT: ABBREVIATED PRESCRIBING INFORMATION

Presentation: Tablets of 4mg, 12mg, 16mg or 20mg sertindole. **Indications:** Treatment of schizophrenia. Not for urgent relief of symptoms in acutely disturbed patients. **Dosage and administration:** Tablets should be taken orally once daily without regard for food. Adults: All patients should be started on 4mg/day. The dose should be increased by 4mg increments after 4-5 days on each dose to the optimum daily maintenance dose range of 12-20mg. The dose may be increased to a maximum of 24mg. Re-titration is necessary if dosing is suspended for more than one week. Children: Not recommended. Mild to moderate hepatic impairment: Slower titration and lower maintenance dose. Elderly: Slower titration and lower maintenance doses may be required. **Contraindications:** Known prolongation of QT interval or combined use of drugs known to prolong QT interval. Clinically significant cardiac disease or uncorrected hypokalaemia. Combined use of drugs that may induce hypokalaemia. **Puritic therapy** may be initiated if necessary but a potassium-sparing agent must be used. Combined use of quinidine or systemic

Serdolect is not sedative, however, patients should be advised not to drive or operate machinery until their individual susceptibility is known. History of diabetes, seizures, Parkinson's disease. Symptoms of orthostatic hypotension may occur and blood pressure should be monitored during initial dose titration and in early maintenance phase. In common with other antipsychotic drugs, Serdolect lengthens the QT interval in some patients (<1.7% of patients). Electrolyte imbalance or combined use of other drugs that inhibit Serdolect metabolism can increase the risk of occurrence of prolonged QT interval. An ECG should be performed prior to use with periodic ECG monitoring during treatment. Serdolect should not be initiated or should be discontinued if the QTc₂ interval exceeds 520 msec. Hypokalaemia and hypomagnesaemia should be corrected and maintained within normal limits during treatment. If signs and symptoms of tardive dyskinesia appear, consider dose reduction or discontinuation. **Drug interactions:** (see also warning boxes). Combined use of agents known to inhibit hepatic isoenzymes may necessitate lower maintenance doses. Combined use of agents

prolonged QT interval. Incidence of EPS adverse events similar to placebo. Overdosage: Symptoms have included somnolence, slurred speech, tachycardia, hypotension and transient prolongation of QT interval. There is no specific antidote. Treatment is supportive and symptomatic. Epinephrine and dopamine should not be used (may exacerbate hypotension). Cardiovascular monitoring recommended. Administration of activated charcoal and laxative should be considered. **Package quantities and basic NHS price:** 4mg tablets, £36.63 for 30 tablet pack, 12mg tablets, £102.55 for 28 tablet calendar pack, 16mg tablets, £102.55 for 28 tablet calendar pack, 20mg tablets, £102.55 for 28 tablet calendar pack. Legal category: POM. **Product Licence numbers:** 4mg: 13761/0001, 12mg: 13761/0003, 16mg: 13761/0004, 20mg: 13761/0005. **Date of last review:** April 1997. Further information is available on request from Lundbeck Limited, Sunningdale House, Caldecotte Lake Business Park, Caldecotte, Milton Keynes, MK15 6JG, UK.

Lundbeck

Change to



'SEROQUEL' (quetiapine)

Prescribing Notes.

Consult Summary of Product Characteristics before prescribing. Special reporting to the CSM required.

Use: Treatment of schizophrenia.

Presentation: Tablets containing 25 mg, 100 mg and 200 mg of quetiapine.

Dosage and Administration: 'Seroquel' should be administered twice daily. Adults: The total daily dose for the first 4 days of therapy is 50 mg (Day 1), 100 mg (Days 2-3), 200 mg (Day 3) and 300 mg (Day 4). From day 4 onwards, titrate to usual effective range of 300 to 450 mg/day. Doses

Elderly patients: Use with caution, starting with 25 mg/day and increasing daily by 25 to 50 mg to an effective dose.

Children and adolescents: Safety and efficacy not evaluated.

Renal and hepatic impairment: Start with 25 mg/day increasing daily by 25 to 50 mg to an effective dose.

Use with caution in patients with hepatic impairment.

Contra-indications: Hypersensitivity to any component of the product.

Precautions: Caution in patients with cardiovascular disease, cerebrovascular disease or other conditions predisposing to hypotension and patients with a history of seizures. Caution in combination with drugs known to prolong the QTc interval, especially in the elderly. Caution in combination with other centrally acting drugs and alcohol.

systemic ketoconazole or erythromycin. If signs and symptoms of tardive dyskinesia appear, consider dosage reduction or discontinuation of 'Seroquel'. In cases of neuroleptic malignant syndrome, discontinue 'Seroquel' and give appropriate medical treatment. 'Seroquel' should only be used during pregnancy if benefits justify the potential risks. Avoid breastfeeding whilst taking 'Seroquel'. Patients should be cautioned about operating hazardous machines, including motor vehicles.

Undesirable events: Somnolence, dizziness, constipation, postural hypotension, dry mouth, asthenia, rhinitis, dyspepsia, limited weight gain, orthostatic hypotension (associated with dizziness), tachycardia and in some patients syncope. Occasional seizures and rarely possible neuroleptic malignant

Seroquel

quetiapine

NEW

- Effective in positive and negative symptoms¹⁻⁴ and improving mood^{*5} in patients with schizophrenia
- Incidence of EPS no different from placebo across the full dose range¹⁻⁴
- Rate of withdrawals due to adverse events no different from placebo⁶
- No requirement for routine blood, BP or ECG monitoring⁷



Changing thinking in schizophrenia.

** Defined as the BPRS item scores of depressive mood, anxiety, guilt feelings and tension*

Small elevations in non-fasting serum triglyceride levels and total cholesterol. Decreases in thyroid hormone levels, particularly total T4 and free T4 usually reversible on cessation. Prolongation of the QTc interval (in clinical trials this was not associated with a persistent increase).

Legal category: POM

Product licence numbers:

25 mg tablet: 12619/0112
100 mg tablet: 12619/0113
200 mg tablet: 12619/0114

Basic NHS cost:

25 mg x 30 tablets £113.10; 100 mg x 30 tablets £169.65;
60 x 100 mg tablets £113.10; 90 x 100 mg tablets £169.65;

Further information is available from:
ZENECA Pharma on 0800 200 123 please ask for
Medical Information, or write to King's Court,
Water Lane, Wilmslow, Cheshire SK9 5AZ.



References

1. Fabre LF, Arvanitis L, Pultz J *et al.* Clin Ther 1995; **17** (No.3): 366-378.
2. Arvanitis LA *et al.* Biol Psychiatry 1997; **42**: 233-246.
3. Small JG, Hirsch SR, Arvanitis LA *et al.* Arch Gen Psychiatry 1997; **54**: 549-557.
4. Borison RL, Arvanitis LA, Miller MS *et al.* J Clin Psychopharmacol 1996; **16** (2):158-169.
5. Data on File, Zeneca Pharmaceuticals.
6. Data on File, Zeneca Pharmaceuticals.
7. 'Seroquel' Summary of Product Characteristics.

CLOZARIL®

clozapine

CLOZARIL ABBREVIATED PRESCRIBING INFORMATION.

The use of CLOZARIL is restricted to patients registered with the CLOZARIL Patient Monitoring Service. Indication Treatment-resistant schizophrenia (patients non-responsive to, or intolerant of, conventional neuroleptics). Presentations 25mg and 100 mg clozapine tablets. **Dosage and Administration** Initiation must be in hospital in-patients and is restricted to patients with normal white blood cell and differential counts. Initially, 12.5 mg once or twice on the first day, followed by one or two 25 mg tablets on the second day. Increase dose slowly, by increments to reach a therapeutic dose within the range of 200 - 450mg daily (see data sheet). The total daily dose should be divided and a larger portion of the dose may be given at night. Once control is achieved a maintenance dose of 150 to 300 mg daily may suffice. At daily doses not exceeding 200mg, a single administration in the evening may be appropriate. Exceptionally, doses up to 900 mg daily may be used. Patients with a history of epilepsy should be closely monitored during CLOZARIL therapy since dose-related convulsions have been reported. Patients with a history of seizures, as well as those suffering from cardiovascular, renal or hepatic disorders, together with the elderly need lower doses (12.5 mg given once on the first day) and more gradual titration. **Contra-Indications** Allergy to any constituents of the formulation. History of drug-induced neutropenia/agranulocytosis, myeloproliferative disorders, uncontrolled epilepsy, alcoholic and toxic psychoses, drug intoxication, comatose conditions, circulatory collapse and/or CNS depression of any cause, severe renal or cardiac failure, active liver disease, progressive liver disease or hepatic failure. **Warning** CLOZARIL can cause agranulocytosis. A fatality rate of up to 1 in 300 has been estimated when CLOZARIL was used prior to recognition of this risk. Since that time strict haematological monitoring of patients has been demonstrated to be effective in markedly reducing the risk of fatality. Therefore, because of this risk its use is limited to treatment-resistant schizophrenic patients: 1. who have normal leucocyte findings and 2. in whom regular leucocyte counts can be performed weekly during the first 18 weeks and at least every two weeks thereafter for the first year of therapy. After one year's treatment, monitoring may be changed to four weekly intervals in patients with stable neutrophil counts. Monitoring must continue throughout treatment and for four weeks after complete discontinuation of CLOZARIL. Patients must be under specialist supervision and CLOZARIL supply is restricted to pharmacies registered with the CLOZARIL Patient Monitoring Service. Prescribing physicians must register themselves, their patients and a nominated pharmacist with the CLOZARIL Patient Monitoring Service. This service provides for the required leucocyte counts as well as a drug supply audit so that CLOZARIL treatment is promptly withdrawn from any patient who develops abnormal leucocyte findings. Each time CLOZARIL is prescribed, patients should be reminded to contact the treating physician immediately if any kind of infection begins to develop, especially any flu-like symptoms. **Precautions** CLOZARIL can cause agranulocytosis. Perform pre-treatment white blood cell count and differential count to ensure only patients with normal findings receive CLOZARIL. Monitor white blood cell count weekly for the first 18 weeks and at least two-weekly for the first year of therapy. After one year's treatment, monitoring may change to four weekly intervals in patients with stable neutrophil counts. Monitoring must continue throughout treatment and for four weeks after complete discontinuation. If signs or symptoms of infection develop an immediate differential count is necessary. If the white blood count falls below $3.0 \times 10^9/L$ and/or the absolute neutrophil count drops below $1.5 \times 10^9/L$, withdraw CLOZARIL immediately and monitor the patient closely, paying particular attention to symptoms suggestive of infection. Re-evaluate any patient developing an infection, or when a routine white blood count is between 3.0 and $3.5 \times 10^9/L$ and/or a neutrophil count between 1.5 and $2.0 \times 10^9/L$, with a view to discontinuing CLOZARIL. Any further fall in white blood/neutrophil count below $1.0 \times 10^9/L$ and/or $0.5 \times 10^9/L$ respectively, after drug withdrawal requires immediate specialised care, where protective isolation and administration of GM-CSF or G-CSF and broad spectrum antibiotics may be indicated. Colony stimulating factor therapy should be discontinued when the neutrophil count returns above $1.0 \times 10^9/L$. CLOZARIL lowers the seizure threshold. Orthostatic hypotension can occur therefore close medical supervision is required during initial dose titration. Patients affected by the sedative action of CLOZARIL should not drive or

operate machinery, administer with caution to patients who participate in activities requiring complete mental alertness. Monitor hepatic function regularly in liver disease. Investigate any signs of liver disease immediately with a view to drug discontinuation. Resume only if LFTs return to normal, then closely monitor patient. Use with care in prostatic enlargement, narrow-angle glaucoma and paralytic ileus. Patients with fever should be carefully evaluated to rule out the possibility of an underlying infection or the development of agranulocytosis. Avoid immobilisation of patients due to increased risk of thromboembolism. Do not give CLOZARIL with other drugs with a substantial potential to depress bone marrow function. CLOZARIL may enhance the effects of alcohol, MAO inhibitors, CNS depressants and drugs with anticholinergic, hypotensive or respiratory depressant effects. Caution is advised when CLOZARIL therapy is initiated in patients who are receiving (or have recently received) a benzodiazepine or any other psychotropic drug as these patients may have an increased risk of circulatory collapse, which, on rare occasions, can be profound and may lead to cardiac and/or respiratory arrest. Caution is advised with concomitant administration of therapeutic agents which are highly bound to plasma proteins. Clozapine binds to and is partially metabolised by the isoenzymes cytochrome P450 1A2 and P450 2D6. Caution is advised with drugs which possess affinity for these isoenzymes. Concomitant cimetidine and high dose CLOZARIL was associated with increased plasma clozapine levels and the occurrence of adverse effects. Concomitant fluoxetine and fluvoxamine have been associated with elevated clozapine levels. Discontinuation of concomitant carbamazepine resulted in increased clozapine levels. Phenytoin decreases clozapine levels resulting in reduced effectiveness of CLOZARIL. No clinically relevant interactions have been noted with antidepressants, phenothiazines and type Ic antiarrhythmics, to date. Concomitant use of lithium or other CNS-active agents may increase the risk of neuroleptic malignant syndrome. The hypertensive effect of adrenaline and its derivatives may be reversed by CLOZARIL. Do not use in pregnant or nursing women. Use adequate contraceptive measures in women of child bearing potential. **Side-Effects** Neutropenia leading to agranulocytosis (See Warning and Precautions). Rare reports of leucocytosis including eosinophilia. Isolated cases of leukaemia and thrombocytopenia have been reported but there is no evidence to suggest a causal relationship with the drug. Most commonly fatigue, drowsiness, sedation. Dizziness or headache may also occur. CLOZARIL lowers the seizure threshold and may cause EEG changes and delirium. Myoclonic jerks or convulsions may be precipitated in individuals who have epileptogenic potential but no previous history of epilepsy. Rarely it may cause confusion, restlessness, agitation and delirium. Extrapyramidal symptoms are limited mainly to tremor, akathisia and rigidity. Tardive dyskinesia reported very rarely. Neuroleptic malignant syndrome has been reported. Transient autonomic effects eg dry mouth, disturbances of accommodation and disturbances in sweating and temperature regulation. Hypersalivation. Tachycardia and postural hypotension, with or without syncope, and less commonly hypertension may occur. In rare cases profound circulatory collapse has occurred. ECG changes, arrhythmias, pericarditis and myocarditis (with or without eosinophilia) have been reported, some of which have been fatal. Rare reports of thromboembolism. Isolated cases of respiratory depression or arrest, with or without circulatory collapse. Rarely aspiration may occur in patients presenting with dysphagia or as a consequence of acute overdosage. Nausea, vomiting and usually mild constipation have been reported. Occasionally obstipation and paralytic ileus have occurred. Asymptomatic elevations in liver enzymes occur commonly and usually resolve. Rarely hepatitis and cholestatic jaundice may occur. Very rarely fulminant hepatic necrosis reported. Discontinue CLOZARIL if jaundice develops. Rare cases of acute pancreatitis have been reported. Both urinary incontinence and retention and priapism have been reported. Isolated cases of interstitial nephritis have occurred. Benign hyperthermia may occur and isolated reports of skin reactions have been received. Rarely hyperglycaemia has been reported. Rarely increases in CPK values have occurred. With prolonged treatment considerable weight gain has been observed. Sudden unexplained deaths have been reported in patients receiving CLOZARIL. **Package Quantities and Price** Community pharmacies only 28 x 25mg tablets: £12.52 (Basic NHS) 28 x 100mg tablets: £50.05 (Basic NHS) Hospital pharmacies only 84 x 25 mg tablets: £37.54 (Basic NHS) 84 x 100 mg tablets: £150.15 (Basic NHS) Supply of CLOZARIL is restricted to pharmacies registered with the CLOZARIL Patient Monitoring Service. **Product Licence Numbers** 25 mg tablets: PL 0101/0228 100 mg tablets: PL 0101/0229 **Legal Category:** POM. CLOZARIL is a registered Trade Mark. Date of preparation, August 1997. Full prescribing information, including Product Data Sheet is available from Novartis Pharmaceuticals UK Ltd. Trading as: SANDOZ PHARMACEUTICALS, Frimley Business Park, Frimley, Camberley, Surrey, GU16 5SG.



NOVARTIS

AUG 97 CLZ 97/13

**BBR
MEDICAL
EDUCATION**

Formerly BPP Medical Education

Intensive weekend courses

MRCPsychiatry Parts I & II
Written and Clinical skills courses

1998
Clinical 9-10 May

BBR Courses are
Stimulating, entertaining and successful.

Telephone or Fax 0181-959-7562

33 Flower Lane, Mill Hill, London NW7



**QUEENSLAND
HEALTH**

QUEENSLAND GETTING ON WITH THE JOB

STAFF SPECIALIST PSYCHIATRIST Mackay Integrated Mental Health Services, Mackay Health Service District, Queensland Australia. Remuneration value up to A\$195,387 p.a. comprising salary between A\$80,285 - A\$101,305 p.a., employer contribution to superannuation (up to 14.65%), annual leave loading (17.5%), private use of fully maintained vehicle, communication package, study and conference leave on full pay with expenses paid, professional indemnity cover, private practice arrangements, employer subsidised accommodation. (MO1.1 to MO1.7) VRN: MO94/97. **Duties/Abilities:** Mackay Integrated Mental Health Services are comprised of three (3) specialist mental health teams. These teams are Adult Mental Health Services, Child and Youth Mental Health Services, and Outreach and Satellite Mental Health Services. All teams operate in an integrated fashion across inpatient and community settings. The Staff Specialist will work in an integrated fashion across designated teams within the service. Internal communication will involve, but not be limited to, consultation and liaison with other mental health services, consumer groups, and a range of government and non-government organisations. Qualifications to include possession of FRANZCP or equivalent and eligibility to register Specialist Psychiatry in Queensland is essential.

Enquiries: Dr Malcolm Stanton 61 7 4968 3893.

Application Kit: 61 7 4968 6530.

Closing Date: Monday, 15th June, 1998.



CONSULTANTS



Choose your quality locum positions now!!!

Short or long term
Competitive rates
All areas of the U.K.
Excellent 'on call' posts

1:7 or better

Documentation/visas arranged

Permanent positions also available

Call **DIRECT MEDICAL APPOINTMENTS**

THE CONSULTANTS CHOICE


for a professional and prompt service

Tel: +44 (0)1792 472525

Fax: +44 (0)1792 472535

Email: medical.appointments@cyberstop.net

**New Brief Pulse ECT with Computer-Assisted
Easy Seizure Monitoring**



Somatics Thymatron™ DGx

- Automatically monitors your choice of EEG-EEG, EEG-EKG, or EEG-EMG and determines EEG and motor seizure lengths.
- Computer-measured seizure quality, including postictal EEG suppression, seizure energy index.
- Up to 8 seconds stimulus duration; pulsewidth as short as 0.5 ms.
- Single dial sets stimulus charge by age; high-dose option available.
- FlexDial™ adjusts pulsewidth and frequency without altering dose.

Distributed in the U.K. by:

DANTEC Electronics, Ltd.
Caronor Way
Royal Portbury
Bristol BS20 9XE
TEL (44) 1275-375333
FAX (44) 1275-375336

Distributed in Australia by:

MEECO Holdings Pty. Ltd.
10 Seville St.
North Parramatta NSW 2151
Australia
TEL (61) 2630-7755
FAX (61) 2630-7365

Distributed in New Zealand by:

WATSON VICTOR, Ltd.
4 Adelaide Rd.
Wellington, New Zealand
TEL (64) 4-385-7699
FAX (64) 4-384-4651

Distributed in Ireland by:

BRENNAN & CO.
Dublin
TEL (353) 1-295-2501
FAX (353) 1-295-2333

Distributed in India by:

DIAGNOSYS
New Delhi
TEL (91) 11-644-0546
FAX (91) 11-622-9229


Distributed in South Africa by:

DELTA SURGICAL
Craighall
TEL (27) 11-792-6120
FAX (27) 11-792-6926

Distributed in U.S.A. and Canada by:



SOMATICS, INC., 910 Sherwood Drive # 17, Lake Bluff, IL, 60044, U.S.A.
Fax: (847) 234-6763; Tel: (847) 234-6761

A man with dark, wavy hair, wearing a white lab coat, is shown from the chest up. He is looking directly at the camera with a slight smile. His right hand is raised, with his index finger pointing upwards. The background is split into a blue left half and a yellow right half. The overall image is framed by a blue border.

As the list of
antipsychotic
agents grows...

...isn't it time to
consider one in
a different class?

CLOZARIL[®]
clozapine

Proven efficacy in treatment
resistant schizophrenia

Efexor[®] XL venlafaxine - Prescribing information Presentation: Capsules containing 75mg or 150mg venlafaxine (as hydrochloride) in an extended release formulation. **Use:** Treatment of depressive illness. **Dosage:** Adults (including the elderly): Usually 75mg, given once daily with food, increasing to 150mg once daily if necessary. The dose can be increased further to 225mg once a day. Dose increments should be made at intervals of approximately 2 weeks or more, but not less than 4 days. Discontinue gradually to avoid possibility of discontinuation effects. **Children:** Contra-indicated below 18 years of age. **Moderate renal or moderate hepatic impairment:** Doses should be reduced by 50%. Not recommended in severe renal or severe hepatic impairment. **Contra-indications:** Pregnancy, lactation, concomitant use with MAOIs, hypersensitivity to venlafaxine or other components, patients aged below 18 years. **Precautions:** Use with caution in patients with myocardial infarction, unstable heart disease, renal or hepatic impairment, or a history of epilepsy (discontinue in event of seizure). Patients should not drive

or operate machinery if their ability to do so is impaired. Possibility of postural hypotension (especially in the elderly). Women of child-bearing potential should use contraception. Prescribe smallest quantity of tablets according to good patient management. Monitor blood pressure with doses >200mg/day. Advise patients to notify their doctor should an allergy develop or if they become or intend to become pregnant. Patients with a history of drug abuse should be monitored carefully. **Interactions:** MAOIs: do not use Efexor XL in combination with MAOIs or within 14 days of stopping MAOI treatment. Allow 7 days after stopping Efexor XL before starting an MAOI. Use with caution in elderly or hepatically-impaired patients taking cimetidine, in patients taking other CNS-active drugs, and in patients taking drugs which inhibit both CYP2D6 and CYP3A4 hepatic enzymes. **Side-effects:** Nausea, insomnia, dry mouth, somnolence, dizziness, constipation, sweating, nervousness, asthenia, abnormal ejaculation/orgasm, anorexia, abnormal vision/accommodation, impatience, vomiting, tremor, abnormal

dreams, vasodilatation, hypertension, rash, agitation, hypertonia, paraesthesia, postural hypotension, reversible increases in liver enzymes, slight increase in serum cholesterol, weight gain or loss, hyponatraemia. **Basic NHS price:** 75mg capsule (PL 00011/0223) - blister pack of 28 capsules: £23.97. 150 mg capsule (PL 00011/0224) - blister pack of 28 capsules: £39.97. **Legal category:** POM. Further information is available upon request from the Product Licence holder: Wyeth Laboratories, Taplow, Maidenhead, Berkshire, SL6 0PH. Date of preparation: August 1997. * trade mark Code no Z777440/0897. WEFX3-UK-JA. References: 1. Muth EA *et al.* *Biochem Pharmacol* 1986; 35(24): 4493-4497. 2. Muth EA *et al.* *Drug Development Research* 1991; 23: 191-199. 3. Rudolph R *et al.* Poster presented at the New Clinical Drug Evaluation Unit (National Institute of Mental Health), Boca Raton, Florida 1997. 4. McPartlin GM *et al.* Poster at the 10th European College of Neuropsychopharmacology meeting, Vienna, September 13th-17th, 1997. 5. Salinas E. *Biol Psychiatry* 1997; 42(Suppl. 1): 244S.

Here comes the Sun


- ◆ EFEXOR XL ACTS DIRECTLY ON BOTH SEROTONIN AND NORADRENALINE^{1,2}
- ◆ PROVEN EFFICACY VS LEADING SSRIs^{3,4}
- ◆ TOLERABILITY^{3,4,5} AND CONVENIENCE YOU EXPECT FROM A FIRST-LINE THERAPY

NEW ONCE DAILY

EFEXOR XL[®]
VENLAFAXINE 75 mg o.d.

Simply effective

Please refer to Summary of Product Characteristics before prescribing Risperdal (risperidone). **USES:** The treatment of acute and chronic schizophrenia, and other psychotic conditions, in which positive and/or negative symptoms are prominent. Risperdal also alleviates affective symptoms associated with schizophrenia. **DOSAGE:** Where medically appropriate, gradual discontinuation of previous antipsychotic treatment while Risperdal therapy is initiated is recommended. Where medically appropriate, when switching patients from depot antipsychotics, consider initiating Risperdal therapy in place of the next scheduled injection. The need for continuing existing antiparkinson medication should be re-evaluated periodically. **Adults:** Risperdal may be given once or twice daily. All patients, whether acute or chronic, should start with 2 mg/day. This should be increased to 4 mg/day on the second day and 6 mg/day on the third day. However, some patients such as first-episode psychotic patients may benefit from a slower rate of titration. From then on the dosage can be maintained unchanged, or further individualised if needed. The usual effective dosage is 4 to 6 mg/day although in some patients an optimal response may be obtained at lower doses. Doses above 10 mg/day may increase the risk of extrapyramidal symptoms and should only be used if the benefit is considered to outweigh the risk. Doses above 16 mg/day should not be used. **Elderly, renal and liver disease:** A starting dose of 0.5 mg bd is recommended. This can be individually adjusted with 0.5 mg bd increments to 1 to 2 mg bd. Risperdal is well tolerated by the elderly. Use with caution in patients with renal and liver disease. Not recommended in children aged less than 15 years. **CONTRA-INDICATIONS, WARNINGS, ETC. Contra-indications:** Known hypersensitivity to Risperdal. **Precautions:** Orthostatic hypotension can occur (alpha-blocking effect). Use with caution in patients with known cardiovascular disease. Consider dose reduction if hypotension occurs. For further sedation, give an additional drug (such as a benzodiazepine) rather than increasing the dose of Risperdal. Drugs with dopamine antagonistic properties have been associated with tardive dyskinesia. If signs and symptoms of tardive dyskinesia appear, the discontinuation of all antipsychotic drugs should be considered. Caution should be exercised when treating patients with Parkinson's disease or epilepsy. Patients should be advised of the potential for weight gain. Risperdal may interfere with activities requiring mental alertness. Patients should be advised not to drive or operate machinery until their individual susceptibility is known. **Pregnancy and lactation:** Use during pregnancy only if the benefits outweigh the risks. Women receiving Risperdal should not breast feed. **Interactions:** Use with caution in combination with other centrally acting drugs. Risperdal may antagonise the effect of levodopa and other dopamine agonists. On initiation of carbamazepine or other hepatic enzyme-inducing drugs, the dosage of Risperdal should be re-evaluated and increased if necessary. On discontinuation of such drugs, the dosage of Risperdal should be re-evaluated and decreased if necessary. **Side effects:** Risperdal is generally well tolerated and in many instances it has been difficult to differentiate adverse events from symptoms of the underlying disease. Common adverse events include: insomnia, agitation, anxiety, headache. Less common adverse events include: somnolence, fatigue, dizziness, impaired concentration, constipation, dyspepsia, nausea/vomiting, abdominal pain, blurred vision, priapism, erectile dysfunction, ejaculatory dysfunction, orgasmic dysfunction, urinary incontinence, rhinitis, rash and other allergic reactions. The incidence and severity of extrapyramidal symptoms are significantly less than with haloperidol. However, the following may occur: tremor, rigidity, hypersalivation, bradykinesia, akathisia, acute dystonia. If acute, these symptoms are usually mild and reversible upon dose reduction and/or administration of antiparkinson medication. Rare cases of Neuroleptic Malignant Syndrome have been reported. In such an event, all antipsychotic drugs should be discontinued. Occasionally, orthostatic dizziness, hypotension (including orthostatic), tachycardia (including reflex) and hypertension have been observed. An increase in plasma prolactin concentration can occur which may be associated with galactorrhoea, gynaecomastia and disturbances of the menstrual cycle. Oedema and increased hepatic enzyme levels have been observed. A mild fall in neutrophil and/or thrombocyte count has been reported. Rare cases of water intoxication with hyponatraemia, tardive dyskinesia, body temperature dysregulation and seizures have been reported. **Overdosage:** Reported signs and symptoms include drowsiness and sedation, tachycardia and hypotension, and extrapyramidal symptoms. A prolonged QT interval was reported in a patient with concomitant hypokalaemia who had ingested 360 mg. Establish and maintain a clear airway, and ensure adequate oxygenation and ventilation. Gastric lavage and activated charcoal plus a laxative should be considered. Commence cardiovascular monitoring immediately, including continuous electrocardiographic monitoring to detect possible arrhythmias. There is no specific antidote, so institute appropriate supportive measures. Treat hypotension and circulatory collapse with appropriate measures. In case of severe extrapyramidal symptoms, give anticholinergic medication. Continue close medical supervision and monitoring until the patient recovers. **PHARMACEUTICAL PRECAUTIONS:** Tablets: Store below 30°C. Liquid: Store below 30°C, protect from freezing. **LEGAL CATEGORY POM. PRESENTATIONS, PACK SIZES, PRODUCT LICENCE NUMBERS & BASIC NHS COSTS:** White, oblong tablets containing 1 mg risperidone in packs of 20. PL 0242/0186 £13.45. Pale orange, oblong tablets containing 2 mg risperidone in packs of 60. PL 0242/0187 £79.56. Yellow, oblong tablets containing 3 mg risperidone in packs of 60. PL 0242/0188 £117.00. Green, oblong tablets containing 4 mg risperidone in packs of 60. PL 0242/0189 £154.44. Yellow, circular tablets containing 6 mg risperidone in packs of 20. PL 0242/0317 £108.20. Starter packs containing 6 Risperdal 1 mg tablets are also available £4.15. Clear, colourless solution containing 1 mg risperidone per ml in bottles containing 100 ml. PL 0242/0199 £65.00. **FURTHER INFORMATION IS AVAILABLE FROM THE PRODUCT LICENCE HOLDER:** Janssen-Cilag Ltd, Saunderton, High Wycombe, Buckinghamshire HP14 4HJ. APIVER 140797. **References:** 1. Brecher M, Lemmens P, Van Baelen B. Presented at the Annual Meeting of the American College of Neuropsychiatry, December 9-13, 1996, San Juan, Puerto Rico. 2. Data on file, Janssen-Cilag Ltd. MJE 12/97.



For the
mind in
turmoil

Campral ECacamprate

Presentation: Off-white round enteric-coated tablets, containing 333mg acamprate calcium. Printed on one side with 333. **Properties:** Acamprate may act by stimulating GABAergic inhibitory neurotransmission and antagonising excitatory amino acids, particularly glutamic acid. **Indication:** Maintenance of abstinence in alcohol dependent patients. It should be combined with counselling. **Dosage and Administration:** *Adults* \geq 60kg: 6 tablets per day (2 tablets taken three times daily with meals) *Adults* < 60kg: 4 tablets per day (2 tablets in the morning, 1 at noon and 1 at night with meals). Recommended treatment period one year, starting as

patient relapses. *Elderly:* Not recommended. *Children:* Not recommended. **Contraindications:** Known hypersensitivity to the drug, renal insufficiency (serum creatinine > 120 micromol/L), severe hepatic failure (Childs-Pugh classification C), pregnancy, lactation. **Precautions and Warnings:** Campral EC does not constitute treatment during the withdrawal period. **Interactions:** None observed in studies with diazepam, disulfiram or imipramine. The concomitant intake of alcohol and acamprate does not affect the pharmacokinetics of either alcohol or acamprate. **Side Effects:** Diarrhoea, and less frequently nausea, vomiting and abdominal pain; pruritus. These are usually mild and transient. An occasional maculopapular rash and rare

reported. Campral EC should not impair the patient's ability to drive or operate machinery. **Overdose:** Gastric lavage; should hypercalcaemia occur, treat patient for acute hypercalcaemia. **Legal Category:** POM. **Pharmaceutical Precautions:** None. **Package Quantities and Basic NHS Price:** 84 blister packed tablets £24.95. **Marketing Authorisation Number/Holder:** 13466/0001, Lipha SA, Lyon, France. **Date of Preparation:** August 1997. Further information is available on request from Merck Pharmaceuticals, Harrier House, High Street, West Drayton, Middlesex, UB7 7QG. **Date of Preparation:** March 1998. March 1998.ZZ10104

BRAIN BIOCHEMISTRY ADAPTS TO
LIFE WITH ALCOHOL

CAMPRAL EC HELPS BRAIN BIOCHEMISTRY ADAPT TO
LIFE WITHOUT IT



Non-aversive **Campral EC** modifies the biochemical mechanisms that cause craving in patients who are adapting to a life without alcohol. To find out how this unique drug can support the vital role of counselling in helping to prevent relapse simply call

0 8 0 0 9 8 0 7 0 5 5

A close-up, artistic photograph of a person's face, focusing on the eye and hand. The person has light-colored eyes and is looking towards the camera. A hand is positioned near the eye, with fingers slightly curled. The lighting is soft, creating a gentle and intimate atmosphere.

p e a c e
at last

- ▶ Power to relieve positive *and* negative symptoms in schizophrenia
- ▶ Placebo levels of EPS at usual effective doses¹
- ▶ Over 18 million patient months experience worldwide²



ONCE DAILY
RisperdalTM
RISPERIDONE

POWER you can trust



Books Beyond Words
Series from Gaskell

You're on Trial

Sheila Hollins, Glynis Murphy
and Isabel Clare,
illustrated by Beth Webb

The pictures and text in this book are intended to show the likely events when someone with learning disabilities or mental health needs comes into contact with the criminal justice system. The intended readership is people with learning disabilities or difficulties or mental health needs. The 'story' is told in pictures without any words although there is a text at the back of the book which may be useful too. You can make any story you like from the book as it will fit any crime and any verdict.

This book is a joint publication between the Royal College of Psychiatrists and St. George's Hospital Medical School. The authors all work with people with learning disabilities.

● £10.00 ● 72pp. ● 1996 ● ISBN 1 901242 00 5

*Also available in this series:
You're under Arrest, price £10.00.*

*Gaskell books are available from the Publications
Department, Royal College of Psychiatrists,
17 Belgrave Square, London SW1X 8PG
(Tel. +44(0)171 235 2351, extension 146).*

*The latest information on College publications is
available on the INTERNET at:
<http://www.demon.co.uk/rcpsych/>*

ZISPIN Prescribing Information

Presentation: Blister strips of 28 tablets each containing 30 mg of mirtazapine. **Uses:** Treatment of depressive illness. **Dosage and administration:** The tablets should be taken orally, if necessary with fluid, and swallowed without chewing. **Adults and elderly:** The effective daily dose is usually between 15 and 45 mg. **Children:** Not recommended. The clearance of mirtazapine may be decreased in patients with renal or hepatic insufficiency. Zispin is suitable for once-a-day administration, preferably as a single night-time dose. Treatment should be continued until the patient has been completely symptom-free for 4 - 6 months. **Contraindications:** Hypersensitivity to mirtazapine or any ingredients of Zispin. **Precautions and warnings:** Reversible white blood cell disorders including agranulocytosis, leukopenia and granulocytopenia have been reported with Zispin. The physician should be alert to symptoms such as fever, sore throat, stomatitis or other signs of infection; if these occur, treatment should be stopped and blood counts taken. Patients should also be advised of the importance of these symptoms. Careful dosing as well as regular and close monitoring is necessary in patients with: epilepsy and organic brain syndrome; hepatic or renal insufficiency; cardiac diseases; low blood pressure. As with other antidepressants care should be taken in patients with: micturition disturbances like prostate hypertrophy, acute narrow-angle glaucoma and increased intra-ocular pressure and diabetes mellitus. Treatment should be discontinued if jaundice occurs. Moreover, as with other antidepressants, the following should be taken into account: worsening of psychotic symptoms can occur when antidepressants are administered to patients with schizophrenia or other psychotic disturbances; when the depressive phase of manic-depressive psychosis is being treated, it can transform into the manic phase. Zispin has sedative properties and may impair concentration and alertness. **Interactions:** Mirtazapine may potentiate the central nervous dampening action of alcohol; patients should therefore be advised to avoid alcohol during treatment with Zispin; Zispin should not be administered concomitantly with MAO inhibitors or within two weeks of cessation of therapy with these agents; Mirtazapine may potentiate the sedative effects of benzodiazepines; In vitro data suggest that clinically significant interactions are unlikely with mirtazapine. **Pregnancy and lactation:** The safety of Zispin in human pregnancy has not been established. Use during pregnancy is not recommended. Women of child bearing potential should employ an adequate method of contraception. Use in nursing mothers is not recommended. **Adverse reactions:** The following adverse effects have been reported: **Common (>1/100):** Increase in appetite and weight gain. Drowsiness/sedation, generally occurring during the first few weeks of treatment. (N.B. dose reduction generally does not lead to less sedation but can jeopardize antidepressant efficacy). **Less common (<1/1000):** Oedema and accompanying weight gain. Reversible agranulocytosis has been reported as a rare occurrence. (Orthostatic) hypotension. Exanthema. Mania, convulsions, tremor, myoclonus. **Overdosage:** Toxicity studies in animals suggest that clinically relevant cardiotoxic effects will not occur after overdosing with Zispin. Experience in clinical trials and from the market has shown that no serious adverse effects have been associated with Zispin in overdose. Symptoms of acute overdosage are confined to prolonged sedation. Cases of overdose should be treated by gastric lavage with appropriate symptomatic and supportive therapy for vital functions. **Marketing authorization number:** PL 0065/0145 **Legal category:** POM **Basic NHS cost:** £24 for 28 tablets of 30 mg.



For further information, please contact:
Organon Laboratories Limited, Cambridge Science
Park, Milton Road, Cambridge CB4 4FL
Telephone: 01223 423445. Fax: 01223 424368.

MIRTAZAPINE
ZISPIN 30[▼] mg
The NaSSA

**Strong
yet
gentle**

in

depression





Add life to living with schizophrenia

Solian is a new benzamide antipsychotic, with the ability to treat both the positive¹ and negative² symptoms of schizophrenia.

Solian offers a lower incidence of EPS than standard neuroleptics such as haloperidol,³ as well as avoiding some of the drawbacks of certain atypicals: it does not require routine cardiovascular^{4,5} or haematological⁶

monitoring and patients gain significantly less weight than those treated with risperidone.²

So when patients need the ability to cope with their condition, Solian has the power to treat their positive¹ and their negative² symptoms whilst still allowing them to do the everyday things that the rest of us take for granted.

Solian[®]
AMISULPRIDE



Efficacy that patients can live with

Prescribing Information - Solian 200 and Solian 50 ▼ **Presentation:** Solian 200mg tablets contain 200mg amisulpride and Solian 50mg tablets contain 50mg amisulpride. **Indication:** Acute and chronic schizophrenia in which positive and/or negative symptoms are prominent. **Dosage:** Acute psychotic episodes: 400-800mg/day, increasing up to 1200mg/day according to individual response (dose titration not required), in divided doses. Predominantly negative symptoms: 50-300mg once daily adjusted according to individual response. Elderly: administer with caution due to the risk of hypotension or sedation. Renal insufficiency: reduce dose and consider intermittent therapy. Hepatic insufficiency: no dosage adjustment necessary. Children: contraindicated in children under 15 years (safety not established). **Contraindications:** Hypersensitivity; concomitant prolactin-dependent tumours e.g. pituitary gland prolactinaemias and breast cancer; pheochromocytoma; children under 15 years; pregnancy; lactation; women of child-bearing potential unless using adequate contraception. **Warning and Precautions:** As with all neuroleptics, patients should be monitored for tardive dyskinesia. Caution in patients with a history of epilepsy and Parkinson's disease. **Interactions:** Caution in

hypotensive medications, and dopamine agonists. **Side Effects:** Insomnia, anxiety, agitation. Less commonly somnolence and GI disorders. In common with other neuroleptics: Solian causes a reversible increase in plasma prolactin levels; Solian may also cause weight gain, acute dystonia, extrapyramidal symptoms, tardive dyskinesia, hypotension and bradycardia; rarely, allergic reactions, seizures and neuroleptic malignant syndrome have been reported. **Basic NHS Cost:** Blister packs of: 200mg x 60 tablets - £60.00; 200mg x 90 tablets - £90.00; 50mg x 60 tablets - £16.45; 50mg x 90 tablets - £24.69. **Legal Category:** POM. **Product Licence Numbers:** Solian 200 - PL 15819/0002, Solian 50 - PL 15819/0001. **Product Licence Holder:** Lorex Synthelabo UK and Ireland Ltd, Foundation Park, Roxborough Way, Maidenhead, Berks, SL6 3UD. **References:** 1. Freeman HL. *Int Clin Psychopharmacol* 1997;12(Suppl 2):S11-S17. 2. Möller HJ. 6th World Congress of Biological Psychiatry, Nice, France, June 22-27 1997. 3. Coukell AJ, Spencer CM, Benfield P. *CNS Drugs (Adis)* 1996 Sep 6 (3):237-256. 4. Solian SPC. Lorex Synthelabo. 5. Sertindole SPC. Lundbeck Ltd. 6. Clozapine SPC.

SYNTHELABO
CNS DIVISION

True leadership has to be earned.

ASSOCIATED ANXIETY

Prozac has a proven record of efficacy in depression,^{1,2,3} with a confirmed indication in depression with or without associated anxiety symptoms.⁴

A possible reason why Prozac has earned its status around the world.

PROZAC

fluoxetine

The World's No.1 prescribed antidepressant brand.¹

'PROZAC' ABBREVIATED PRESCRIBING

INFORMATION (FLUOXETINE HYDROCHLORIDE)

Presentation Capsules containing 20mg or 60mg fluoxetine, as the hydrochloride. Liquid containing 20mg fluoxetine, as the hydrochloride, per 5ml syrup. **USPS Depression TREATMENT OF THE SYMPTOMS OF DEPRESSIVE ILLNESS, WITH OR WITHOUT ASSOCIATED ANXIETY SYMPTOMS.** *Obsessive-compulsive disorder. Bulimia nervosa:* For the reduction of binge-eating and purging activity. **Dosage and Administration** (For full information, see data sheet.) For oral administration to adults only. *Depression, with or without associated anxiety symptoms - adults and the elderly:* A dose of 20mg/day is recommended. *Obsessive-compulsive disorder:* 20mg/day to 60mg/day. A dose of 20mg/day is recommended as the initial dose. *Bulimia - adults and the elderly:* A dose of 60mg/day is recommended. Because of the long elimination half-lives of the parent drug (1-3 days after acute administration; may be prolonged to 4-6 days after chronic administration) and its major metabolite (average 9.3 days), active drug substance will persist in the body for several weeks after dosing is stopped. The capsule and liquid dosage forms are bioequivalent. **Children:** Not recommended. *Patients with renal and/or hepatic dysfunction:* See 'Contra-indications' and 'Precautions' sections. **Contra-indications** Hypersensitivity to fluoxetine. Prozac should not be administered to patients with severe renal failure (GFR below 10ml/min). *Use in nursing mothers:* Prozac should not be prescribed to nursing mothers. **Monoamine oxidase inhibitors:** At

initiation of therapy with an MAOI. Serious, sometimes fatal reactions (including hyperthermia, rigidity, myoclonus, autonomic instability and mental status changes that include extreme agitation, progressing to delirium and coma) have been reported with concomitant use or when fluoxetine had been recently discontinued and an MAOI started. Some cases presented with features resembling neuroleptic malignant syndrome. **Warnings** *Rash and allergic reactions:* Angioneurotic oedema, urticaria and other allergic reactions have been reported. Upon appearance of rash, or of other allergic phenomena for which an alternative aetiology cannot be identified, Prozac should be discontinued. **Pregnancy:** Use of Prozac should be avoided unless there is no safer alternative. **Precautions** Prozac should be discontinued in any patient who develops seizures. Prozac should be avoided in patients with unstable epilepsy; patients with controlled epilepsy should be carefully monitored. There have been rare reports of prolonged seizures in patients on fluoxetine receiving ECT treatment. A lower dose of Prozac, eg, alternate day dosing, is recommended in patients with significant hepatic dysfunction or mild to moderate renal failure (GFR 10-50ml/min). Caution is advisable when Prozac is used in patients with acute cardiac disease. Prozac may cause weight loss which may be undesirable in underweight depressed patients. In diabetics, fluoxetine may alter glycaemic control. There have been reports of abnormal bleeding by several patients, however, a causal relationship to fluoxetine and clinical importance are unclear. **Drug interactions:**

cytochrome P450IID6 isoenzyme system, concomitant therapy with other drugs also metabolised by this system, and which have a narrow therapeutic index (eg, carbamazepine, tricyclic antidepressants), should be initiated at or adjusted to the low end of their dose range. Greater than 2-fold increases of previously stable plasma levels of cyclic antidepressants have been observed when Prozac has been administered in combination. Agitation, restlessness and gastro-intestinal symptoms have been reported in a small number of patients receiving fluoxetine in combination with tryptophan. Patients on stable phenytoin doses have developed elevated plasma concentrations and clinical phenytoin toxicity after starting fluoxetine. **For further information, see data sheet.** **Adverse Effects** *Asithenia, fever, nausea, diarrhoea, dry mouth, appetite loss, dyspepsia, vomiting, nausea, decreased LFTs, headache, nervousness, insomnia, drowsiness, anxiety, tremor, dizziness, fatigue, decreased libido, seizures, hypomania or mania, dyskinesia, movement disorders, neuroleptic malignant syndrome-like events, pharyngitis, dyspnoea, pulmonary events (including inflammatory processes and/or fibrosis), rash, urticaria, vasculitis, excessive sweating, arthralgia, myalgia, serum sickness, anaphylactoid reactions, hair loss, sexual dysfunction.* The following have been reported in association with fluoxetine but no causal relationship has been established: aplastic anaemia, cerebral vascular accident, confusion, ecchymoses, eosinophilic pneumonia, gastro-intestinal haemorrhage, hyperprolactinaemia, immune-related


Hyponaatraemia (including serum sodium below 110mmol/l) has been rarely reported. This appears to be reversible upon discontinuation. **Overdosage** On the evidence available, fluoxetine has a wide margin of safety in overdose. Since introduction, reports of death, attributed to overdosage of fluoxetine alone, have been extremely rare. One patient who reportedly took 3000mg of fluoxetine experienced 2 grand mal seizures that remitted spontaneously. **Legal Category** POM **Product Licence Numbers** 0006/0195 0006/0198 0006/0272 **Basic NHS Cost** £20.77 per pack of 30 capsules (20mg). £67.85 per pack of 98 capsules (20mg). £62.31 per pack of 30 capsules (60mg). £19.39 per 70ml bottle. **Date of Preparation or Last Review** October 1996. **Full Prescribing Information is Available From** Distia Products Limited, Dextira Court, Chapel Hill, Basingstoke, Hampshire, RG21 5SY. Telephone: Basingstoke (01256) 52011 'PROZAC' is a Distia trademark

References: 1. Data on file, Distia Products Ltd. 2. Tignol J. *J Clin Psychopharm* 1993; 13 (6, suppl. 2): 185-225. 3. Bennie EH, Mullin JM, Martindale JJ. *J Clin Psychiatry* 1995; 56: 229-237. 4. Prozac: Data Sheet 24M.

Date of preparation: May 1997

PP 906

<http://oml.com/Usage%20in%20nursing%20mothers>



Because
community
re-integration
is not that
simple.

ABBREVIATED PRESCRIBING INFORMATION:

Presentation: Coated tablets containing 5mg, 7.5mg or 10mg of olanzapine. The tablets also contain lactose.
Uses: Schizophrenia, both as initial therapy and for maintenance of response. **Further Information:** In studies of patients with schizophrenia and associated depressive symptoms, mood score improved significantly more with olanzapine than with haloperidol. **Pharmacodynamics:** Olanzapine was associated with significantly greater improvements in both negative and positive schizophrenic symptoms than placebo or comparator in most studies.
Dosage and Administration: 10mg/day orally, as a single dose without regard to meals. Dosage may subsequently be adjusted within the range of 5-20mg daily. An increase to a dose greater than the routine therapeutic dose of 10mg/day is recommended only after clinical assessment. **Children:** Not recommended under 18 years of age. **The elderly:** A lower starting dose (5mg/day) is not routinely indicated but should be considered when clinical factors warrant. **Hepatic and/or renal impairment:** A lower starting dose (5mg) may be considered. When more than one factor is present which might result in slower metabolism (female gender, elderly age, non-smoking status), consideration should be given to decreasing the starting dose. Dose escalation should be conservative in such patients. **Contra-indications:** Known hypersensitivity to any ingredient of the product. Known risk for narrow-angle glaucoma.
Warnings and Special Precautions: Caution in patients with prostatic hypertrophy, or paralytic ileus and related conditions. Caution in patients with elevated ALT and/or AST, signs and symptoms of hepatic impairment, pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic drugs. As with other neuroleptic drugs, caution in patients with low leucocyte and/or neutrophil counts for any reason, a history of drug-induced bone marrow depression/toxicity, bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and in patients with hyper eosinophilic conditions or with myeloproliferative disease. Thirty-two patients with clozapine-related neutropenia or agranulocytosis histories received olanzapine without decreases in baseline neutrophil counts. Although, in clinical trials, there were no reported cases of NMS in patients receiving olanzapine, if such an event occurs, or if there is unexplained high fever, all antipsychotic drugs, including olanzapine, must be discontinued. Caution in patients who have a history of seizures or have conditions associated with seizures. If signs or symptoms of tardive dyskinesia appear a dose reduction or drug discontinuation should be considered. Caution when taken in combination with other centrally acting drugs and alcohol. Olanzapine may antagonise the effects of direct and

Antipsychotic Efficacy for First-line Use

ZYPREXA
Olanzapine 
Making Community Re-integration the Goal

elderly. However, blood pressure should be measured periodically in patients over 65 years, as with other antipsychotics. As with other antipsychotics, caution when prescribed with drugs known to increase QTc interval, especially in the elderly. In clinical trials, olanzapine was not associated with a persistent increase in absolute QT intervals. **Interactions:** Metabolism may be induced by concomitant smoking or carbamazepine therapy. **Pregnancy and Lactation:** Olanzapine had no teratogenic effects in

animals. Because human experience is limited, olanzapine should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus. Olanzapine was excreted in the milk of treated rats but it is not known if it is excreted in human milk. Patients should be advised not to breast feed an infant if they are taking olanzapine. **Driving, etc:** Because olanzapine may cause somnolence, patients should be cautioned about operating hazardous machinery, including motor vehicles. **Undesirable Effects:** The only frequent (>10%) undesirable effects associated with the use of olanzapine in clinical trials were somnolence and weight gain. Occasional undesirable effects included dizziness, increased appetite, peripheral oedema, orthostatic hypotension, and mild, transient anticholinergic effects, including constipation and dry mouth. Transient, asymptomatic elevations of hepatic transaminases, ALT, AST have been seen occasionally. Olanzapine-treated patients had a lower incidence of parkinsonism, akathisia and dystonia in trials compared with titrated doses of haloperidol. Photosensitivity reaction or high creatinine phosphokinase were reported rarely. Plasma prolactin levels were sometimes elevated, but associated clinical manifestations were rare. Asymptomatic haematological variations were occasionally seen in trials. *For further information see summary of product characteristics.* **Legal Category:** POM. **Marketing Authorisation Numbers:** EU/1/96/022/004 EU/1/96/022/006 EU/1/96/022/008 EU/1/96/022/009 EU/1/96/022/010. **Basic NHS Cost:** £52.73 per pack of 28 x 5mg tablets. £105.47 per pack of 28 x 10mg tablets. £158.20 per pack of 56 x 7.5mg tablets. £210.93 per pack of 56 x 10mg tablets. **Date of Preparation or Last Review:** April 1997. **Full Prescribing Information is Available From:** Eli Lilly and Company Limited, Dextra Court, Chapel Hill, Basingstoke, Hampshire RG21 5SY. Telephone: Basingstoke (01256) 315000.



July 13, 1998

Agenda

- 18.00 PM **Cocktail Reception**
- 18.15 PM **Welcome & Introduction**
*Alistair Burns, MD, Chairman
Manchester
United Kingdom*
- 18.20 **Pediatric OCD:
Characteristics and Treatment**
*John March, MD
Durham, North Carolina
USA*
- 18.40 **The Prevalence and Treatment
of Comorbid MDD and OCD**
*Rudolf Hoehn-Saric, MD
Baltimore, Maryland
USA*
- 19.00 **Epidemiologic Perspectives:
Comorbidity of Panic Disorder
and Depression**
*Borwin Bandelow, MD
Göttingen
Germany*
- 19.20 **Effective and Comprehensive
Management of Patients
with Panic Disorder**
*Christer Allgulander, MD
Huddinge
Siceden*
- 19.40 **Late Life Depression:
Improving Cognition, Anxiety,
Energy, and Sleep**
*Bernard Groulx, MD
Ste-Anne de Bellevue, Quebec
Canada*
- 20.00 **Question & Answer Session**
Faculty Panel
- 20.15 **Dinner Buffet**
- 20.45 **Adjournment**



Depression, Panic, and OCD:
**Improving Patient
Management** *Through the
Life Cycle*

Argyll Suite
Moat House Hotel

Glasgow
Scotland

*XXIst Congress of the
Collegium Internationale
Neuro-Psychopharmacologicum*

To register for this program, please
call Pharmedica Communications, Inc.,
at 1-800-835-7633 USA
or E-mail cinp@pharmedica.com



*This program is made possible through
an unrestricted educational grant from
Pfizer Inc.*

Presentation: White to off-white tablets each containing modafinil 100 mg. **Indication:** Narcolepsy. **Dosage:** Adults: 200-400 mg daily either as two divided doses in the morning and at noon or as a single morning dose according to response. **Elderly:** Treatment should start at 100 mg daily which may be increased subsequently to the maximum adult daily dose in the absence of renal or hepatic impairment. **Severe renal or hepatic impairment:** Reduce dose by half (100-200 mg daily). **Children:** See contra-indications. **Contra-indications:** Pregnancy, lactation, use in children, moderate to severe hypertension, arrhythmia, hypersensitivity to modafinil or any excipients used in Provigil. **Warnings and precautions:** Patients with major anxiety should only receive Provigil treatment in a specialist unit. Sexually active women of child-bearing potential should be established on a contraceptive programme before starting treatment. Blood pressure and heart rate should be monitored in hypertensive patients. Provigil is not recommended in patients with a history of left ventricular hypertrophy or ischaemic ECG changes, chest pain, arrhythmia or other clinically significant manifestations of mitral valve prolapse in association with CNS stimulant use. Studies of modafinil have demonstrated a low potential for dependence although the possibility of this occurring with long-term use cannot be entirely excluded. **Drug interactions:** Induction of cytochrome P-450 isoenzymes has been observed *in vitro*. Effectiveness of oral

no clinically relevant interaction was seen in a single dose interaction study of Provigil and clomipramine. However, patients receiving such medication should be carefully monitored. Care should be observed with co-administration of anti-convulsant drugs. **Side effects:** Nervousness, excitation, aggressive tendencies, insomnia, personality disorder, anorexia, headache, CNS stimulation, euphoria, abdominal pain, dry mouth, palpitation, tachycardia, hypertension and tremor have been reported. Nausea and gastric discomfort may occur and may improve when tablets are taken with meals. Pruritic skin rashes have been observed occasionally. Buccofacial dyskinesia has been reported very rarely. A dose related increase in alkaline phosphatase has been observed. **Basic NHS cost:** Packs of 30 blister packed 100 mg tablets: £60.00. **Marketing authorisation number:** 16260/0001. **Marketing authorisation holder:** Cephalon UK Ltd., 11/13 Frederick Sanger Road, Surrey Research Park, Guildford, GU2 5YD. **Legal category:** POM. **Date of preparation:** January 1998. Provigil and Cephalon are registered trademarks. **References:** 1. Mitler MM. Sleep 1994; 17: S103-S106. 2. Data on file, Cephalon [3]. 3. Lin JS *et al.* Proc Natl Acad Sci USA 1996; 93 (24): 14128-14133. 4. Simon P *et al.* Eur Neuropsychopharmacol 1995; 5: 509-514.



WAKE UP LITTLE SUZIE, WAKE UP

Excessive sleepiness associated with narcolepsy frequently has a disastrous effect on patients' lives, by impairing their physical, social and emotional well being. Unfortunately, treatment with amphetamines is often associated with a high incidence of unpleasant side effects, which limit their overall benefit.¹

Now Provigil (modafinil) – a novel wake promoting agent – offers new advantages in narcolepsy. The clinical efficacy of Provigil has been demonstrated in large controlled clinical studies. In one study,² one in five people with severe narcolepsy reached normal levels of daytime wakefulness while receiving Provigil.

Provigil selectively activates the hypothalamus³ and differs greatly from amphetamines in its pharmacology.⁴ Consequently the incidence of amphetamine like side effects is very low.

PROVIGIL[®]
MODAFINIL

DUTONIN™ Abbreviated Prescribing Information
PRESENTATION: Tablets containing 50mg, 100mg and 200mg nefazodone hydrochloride. **INDICATIONS:** Symptomatic treatment of all types of depressive illness, including depressive syndromes accompanied by anxiety or sleep disturbances. **DOSAGE:** Usual therapeutic dose 200mg twice daily. Range – 100mg - 600mg daily, see Summary of Product Characteristics. **Elderly:** Usual therapeutic dose 50 - 200mg twice daily. **Renal and Hepatic Impairment:** Lower end of dose range. **Children:** Not recommended below the age of 18 years. **CONTRA-INDICATIONS:** Hypersensitivity to nefazodone hydrochloride, tablet excipients or phenylpiperazine antidepressants.



Bristol-Myers Squibb
Pharmaceuticals Limited

WARNINGS/ PRECAUTIONS: Hepatic or renal impairment. Patients at high risk of self harm should be kept under close supervision during

initial treatment phase. Modest decrease in some psychomotor function tests but no impairment of cognitive function. Not recommended in pregnancy and lactation. Use with caution in epilepsy, history of mania/hypomania, recent M.I., unstable heart disease. No clinical studies available on concurrent use of ECT and nefazodone. **DRUG INTERACTIONS:** Caution is advised when combining with other CNS medication, digoxin, products metabolised by Cytochrome P₄₅₀III_{A4}; see Summary of Product Characteristics. **SIDE EFFECTS:** Most frequently asthenia, dry mouth, nausea, constipation, somnolence, light-headedness and dizziness; see Summary of Product Characteristics. **OVERDOSAGE:** There is no specific antidote for nefazodone. Gastric lavage recommended for suspected overdose. Treatment should be symptomatic and supportive in the case of hypotension or excessive sedation. **PRODUCT LICENCE NUMBERS:** Dutonin Tablets 50mg PL 11184/0027; Dutonin Tablets 100mg PL 11184/0028; Dutonin Tablets 200mg

PL 11184/0029, **PRODUCT LICENCE HOLDER:** Bristol-Myers Squibb Pharmaceuticals Ltd. **BASIC NHS PRICE:** Treatment Initiation Pack containing 50mg tablets 14, 100mg tablets 14, 200mg tablets 28 – £16.80; 100mg tablets 56 – £16.80; 200mg tablets 56 – £16.80. **LEGAL CATEGORY:** POM. Further information from: Medical Information, Bristol-Myers Squibb House, 141-149 Staines Road, Hounslow, Middlesex, TW3 3JA. Telephone: 0181-754-3740. Date of preparation: July 1997. **REFERENCES:** 1. Armitage R. *Journal of Psychopharmacology* 1996; 10(suppl1): 22-25. 2. Sharpley AL *et al.* *Psychopharmacology* 1996; 126: 50-54. 3. Armitage R *et al.* *J Clin Psychopharmacol* 1997; 17(3): 161-168. 4. Armitage R *et al.* Presented at the European College of Neuropsychopharmacology (ECNP), 30 September - 4 October 1995, Venice, Italy. 5. Fontaine R *et al.* *J Clin Psychiatry* 1994; 55(6): 234-241. 6. Gillin JC *et al.* *J Clin Psychiatry* 1997; 58: 185-192.



Waking up early should be her decision, not her problem.

It's not only depression that wakes patients up early. Sleep can also be disturbed by many SSRIs.¹⁻⁴

Dutonin is an excellent choice. Not only does Dutonin effectively relieve depression,⁵ it also normalises sleep patterns.^{3,4,6}

Moreover, Dutonin lifts anxiety symptoms within the first week of treatment.⁵

Waking up early should always be your patient's choice, not their problem.



Makes the difference in depression

DUTONIN™

NEFAZODONE

Mum has Alzheimer's



- **The only once daily** treatment in Alzheimer's disease
- **Effective** in mild to moderately severe stages¹⁻⁴
- **Improves** cognitive symptoms and maintains global function¹⁻⁴
- **Well tolerated** 5mg and 10mg once daily doses.¹⁻⁵

but she knew I was calling today

Aricept[®]

donepezil hydrochloride

Once daily in Alzheimer's

BRIEF PRESCRIBING INFORMATION

ARICEPT[®] (donepezil hydrochloride). Please refer to the SmPC before prescribing ARICEPT 5mg or ARICEPT 10mg. **Indication:** Symptomatic treatment of mild to moderately severe Alzheimer's dementia. **Dose and administration:** **Adults/elderly:** 5mg daily which may be increased to 10mg once daily after at least one month. No dose adjustment necessary for patients with renal or mild-moderate hepatic impairment. **Children:** Not recommended. **Contra-Indications:** Pregnancy. Hypersensitivity to donepezil, piperidine derivatives or any excipients used in ARICEPT. **Lactation:** Excretion into breast milk unknown. Women on donepezil should not breast feed. **Warnings and Precautions:** Initiation and supervision by a physician with experience of Alzheimer's dementia. A caregiver should be available to monitor compliance. Regular monitoring to ensure continued therapeutic benefit, consider discontinuation when evidence of a therapeutic effect ceases. Exaggeration of succinylcholine-type muscle relaxation. Avoid concurrent use of

may be particularly important with "sick sinus syndrome" and supraventricular conduction conditions. Careful monitoring of patients at risk of ulcer disease including those receiving NSAIDs. Cholinomimetics may cause bladder outflow obstruction. Seizures occur in Alzheimer's disease and cholinomimetics have the potential to cause seizures. Care in patients suffering asthma and obstructive pulmonary disease. As with all Alzheimer's patients, routine evaluation of ability to drive/operate machinery. **Drug Interactions:** Experience of use with concomitant medications is limited, consider possibility of as yet unknown interactions. Interaction possible with inhibitors or inducers of Cytochrome P450: use such combinations with care. Possible synergistic activity with succinylcholine-type muscle relaxants, beta-blockers, cholinergic or anticholinergic agents. **Side effects:** Most commonly diarrhoea, muscle cramps, fatigue, nausea, vomiting and insomnia. Other common effects in clinical trials (≥5% and ≥placebo) headache, pain, accident, common cold, abdominal

Presentation and basic NHS cost: Blister packed in strips of 14. ARICEPT 5mg; white, film coated tablets marked 5 and ARICEPT, packs of 28 £68.32. ARICEPT 10mg; yellow, film coated tablets marked 10 and ARICEPT, packs of 28 £95.76. **Marketing authorisation numbers:** ARICEPT 5 mg; PL 10555/0006. ARICEPT 10mg; PL 10555/0007. **Marketing authorisation holder:** Eisai Ltd. **Further information from/Marketed by:** Eisai Ltd, Hammersmith International Centre, 3 Shortlands, London, W6 8EE and Pfizer Ltd, Sandwich, Kent, CT13 9NJ. **Legal category:** POM **Date of preparation:** January 1998. **References:** 1. Rogers SL et al. Neurology 1998; 50: 136-145. 2. Study 301 (accepted for publication, Arch Int Med). 3. Rogers SL, Friedhoff LT. Eur Neuropsychopharmacol 1998; 8 (1): 67-75. 4. Rogers SL et al. Dementia 1996; 7: 293-303. 5. Rogers SL & Friedhoff LT. Eur Neuropsychopharmacol 1997; 7 (suppl. 2): S251.



Another seizure-free day

Wasn't late getting up

Didn't let fish off hook

Didn't fall in water

Didn't have a seizure



TOPAMAX[®]
topiramate

At the end of the day, it works.

Adjunctive treatment for partial seizures with or without secondary generalisation

TOPAMAX Abbreviated Prescribing Information

Please read the data sheet before prescribing

Presentation: Tablets each imprinted "TOP" on one side and strength on the other containing 25mg (white), 50mg (light yellow), 100mg (yellow), and 200mg (salmon) topiramate. **Uses:** Adjunctive therapy of partial seizures, with or without secondarily generalised seizures, in patients inadequately controlled on conventional first line antiepileptic drugs. **Dosage and Administration:** Adults and Elderly: Oral administration. Usual dose: 200mg - 400mg/day in two divided doses. Maximum recommended dose: 800mg/day. Initiate therapy at 50mg bd then titrate to an effective dose. See data sheet for titration. Do not break tablets. It is not necessary to monitor topiramate plasma concentrations. Patients with renal disease/haemodialysis may require a modified titration schedule. (See data sheet). Children: Not recommended. **Contra-indications:** Hypersensitivity to any component of the product. **Precautions and Warnings:** Withdraw all antiepileptic drugs gradually. Maintain adequate hydration to reduce risk of nephrolithiasis (especially increased in those with a predisposition). Drowsiness likely. TOPAMAX may be more sedating than other antiepileptic drugs therefore caution in patients driving or operating machinery, particularly until patients' experience with the drug is established. Do not use in pregnancy unless potential benefit outweighs risk to foetus. Women of child bearing potential should use adequate contraception. Do not use if breastfeeding. **Interactions:** Other Antiepileptic Drugs: No clinically significant effect except in some patients on phenytoin where plasma concentrations

plasma concentrations on sodium valproate addition or withdrawal. Digoxin: A decrease in serum digoxin occurs. Monitor serum digoxin on addition or withdrawal of TOPAMAX. Oral Contraceptives: Should contain not less than 50µg of oestrogen. Ask patients to report any change in bleeding patterns. Others: Avoid agents predisposing to nephrolithiasis. **Side Effects:** In 5% or more: ataxia, impaired concentration, confusion, dizziness, fatigue, paraesthesia, somnolence and abnormal thinking. May cause agitation and emotional lability (which may manifest as abnormal behaviour) and depression. Less commonly: amnesia, anorexia, aphasia, diplopia, nausea, nystagmus, speech disorder, taste perversion, abnormal vision and weight decrease. Increased risk of nephrolithiasis. Venous thromboembolic events reported - causal association not established. **Overdosage:** If ingestion recent, empty stomach. Activated charcoal not recommended. Supportive treatment as appropriate. Haemodialysis is effective in removing topiramate. **Pharmaceutical Precautions:** Store in a dry place at or below 25°C. **Legal Category:** POM **Package Quantities and Prices:** Bottles of 60 tablets. 25mg (PL0242/0301) = £22.02; 50mg (PL0242/0302) = £36.17; 100mg (PL0242/0303) = £64.80; 200mg (PL0242/0304) = £125.83.

Product Licence Holder: JANSSEN-CILAG LIMITED, SAUNDERTON, HIGH WYCOMBE, BUCKINGHAMSHIRE HP14 4HJ. API VER 210397.

Further information is available on request from the Marketing Authorisation Holder: Janssen-Cilag Limited, Saunderton, High Wycombe, Buckinghamshire HP14 4HJ.

© Registered Trademark © Janssen-Cilag Limited 1997

ADVANCED
DIARY DATES

Thinking about management issues in schizophrenia?

As part of a comprehensive programme of initiatives open to psychiatrists, CPNs and pharmacists, we are organising a series of one day multi-disciplinary workshops under the general heading "Therapy Management".

Presentations and discussion groups will focus on the following:

- Factors influencing concordance
- Wider therapeutic options in the management of schizophrenia

Meeting Dates

20 May	Zeneca HQ, Cheshire	18 June	Birmingham
21 May	Southampton	18 June	Essex
22 May	Aylesbury	22 June	Bristol
27 May	London	23 June	Cardiff
8 June	Newcastle	24 June	Wembley
10 June	Cambridge	26 June	Totnes
17 June	Wigan	1 July	Belfast
17 June	Ashford	3 July	Leeds
17 June	Glasgow		

For more information on these multi-disciplinary workshops
please call Sally Heap at Zeneca on 01625 712412.



Granted To ICI Pharmaceuticals



ZENECA

THINKING AHEAD IN PSYCHIATRY

PRESCRIPTION FOR DEPRESSION




Illustration © Janet Atkinson/SIS Paris

Tender loving care and **SEROXAT**
PAROXETINE

Rebuilding the lives
of anxious depressed patients

PRESCRIBING INFORMATION

Presentation: 'Seroxat' Tablets, PL 10592/0001-2, each containing either 20 or 30 mg paroxetine as the hydrochloride. 30 (OP) 20 mg tablets, £20.77; 30 (OP) 30 mg tablets, £31.16. 'Seroxat' Liquid, PL 10592/0092, containing 20 mg paroxetine as the hydrochloride per 10 ml. 150 ml (OP), £20.77.

Indications: Treatment of symptoms of depressive illness of all types including depression accompanied by anxiety. Following satisfactory response, continuation is effective in preventing relapse. Treatment of symptoms and prevention of relapse of obsessive compulsive disorder (OCD). Treatment of symptoms and prevention of relapse of panic disorder with or without agoraphobia.

Dosage: *Adults: Depression:* 20 mg a day. Review response within two to three weeks and if necessary increase dose in 10 mg increments to a maximum of 50 mg according to response.

Obsessive compulsive disorder: 40 mg a day. Patients should be given 20 mg a day initially and the dose increased weekly in 10 mg increments. Some patients may benefit from a maximum dose of 60 mg a day.

Panic disorder: 40 mg a day. Patients should be given 10 mg a day initially and the dose increased weekly in 10 mg increments. Some patients may benefit from a maximum dose of 50 mg a day.

Give orally once a day in the morning with food. The tablets should not be chewed. Continue treatment for a sufficient period, which may be several months for depression or longer for OCD and panic disorder. As with many psychoactive medications abrupt discontinuation should be avoided – see **Adverse reactions**.

Elderly: Dosing should commence at the adult starting dose and may be increased in weekly 10 mg increments up to a maximum of 40 mg a day according to response.

Children: Not recommended.

Severe renal impairment (creatinine clearance <30 ml/min) or severe hepatic impairment: 20 mg a day. Restrict incremental dosage if required to lower end of range.

Contra-indication: Hypersensitivity to paroxetine.

Precautions: History of mania. Cardiac conditions: caution. Caution in patients with epilepsy; stop treatment if seizures develop. Driving and operating machinery.

Drug interactions: Do not use with or within two weeks after MAO inhibitors; leave a two-week gap before starting MAO inhibitor

treatment. Possibility of interaction with tryptophan. Great caution with warfarin and other oral anticoagulants. Use lower doses if given with drug metabolising enzyme inhibitors; adjust dosage if necessary with drug metabolising enzyme inducers. Alcohol is not advised. Use lithium with caution and monitor lithium levels. Increased adverse effects with phenytoin; similar possibility with other anticonvulsants.

Pregnancy and lactation: Use only if potential benefit outweighs possible risk.

Adverse reactions: In controlled trials most commonly nausea, somnolence, sweating, tremor, asthenia, dry mouth, insomnia, sexual dysfunction (including impotence and ejaculation disorders), dizziness, constipation and decreased appetite.

Also spontaneous reports of dizziness, vomiting, diarrhoea, restlessness, hallucinations, hypomania, rash including urticaria with pruritus or angioedema, and symptoms suggestive of postural hypotension. Extrapyrarnidal reactions reported infrequently; usually reversible abnormalities of liver function tests and hyponatraemia described rarely. Symptoms including dizziness, sensory disturbance, anxiety, sleep disturbances, agitation, tremor, nausea, sweating and confusion have been reported following abrupt discontinuation of 'Seroxat'. It is recommended that when antidepressant treatment is no longer required, gradual discontinuation by dose-tapering or alternate day dosing be considered.

Overdosage: Margin of safety from available data is wide. Symptoms include nausea, vomiting, tremor, dilated pupils, dry mouth, irritability, sweating and somnolence. No specific antidote. General treatment as for overdosage with any antidepressant. Early use of activated charcoal suggested.

Legal category: POM. 16.2.98

SB **SmithKline Beecham**
Pharmaceuticals

Welwyn Garden City, Hertfordshire AL7 1EY.

'Seroxat' is a trade mark.

© 1998 SmithKline Beecham Pharmaceuticals.

